Search results
Results from the WOW.Com Content Network
Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
FDA approved CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. This is the first...
Treatment with HIV medicines is called antiretroviral therapy (ART). ART is recommended for everyone with HIV, and people with HIV should start ART as soon as possible. People on ART take a combination of HIV medicines (called an HIV treatment regimen) every day or by schedule (injections).
Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa.
A twice-yearly injectable formulation (Sunlenca) was approved in 2022 for treatment-experienced people with multidrug-resistant HIV. Gilead also makes a 300mg lenacapavir pill that is taken as an initial loading dose and can be used for temporary ‘bridging’ if an injection must be missed.
WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Fortunately, researchers continue to search for new and better HIV treatments that can fill these gaps in care. Here’s a look at some of the most exciting options. When you have HIV, you go on a...
How this new HIV drug therapy works. In essence, lenacapavir tackles the capsid, a conical structure that harbors the RNA (ribonucleic acid) of HIV and other proteins that HIV uses to enter and replicate in human cells.
[On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.
FDA approved Rukobia (fostemsavir), a new antiretroviral medication for adult patients with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully...